Abstract: Provided in certain embodiments herein are methods of prophylaxis of skin cancer in individuals having a heightened risk of skin cancer with a fenretinide agent.
Type:
Application
Filed:
October 28, 2010
Publication date:
January 10, 2013
Applicant:
Revision Therapeutics, Inc.
Inventors:
Barry Scott Butler, Roger Vogel, Nathan L. Mata, Caryn L. Peterson
Abstract: Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.
Type:
Application
Filed:
December 7, 2011
Publication date:
December 6, 2012
Applicant:
ReVision Therapeutics, Inc.
Inventors:
Kenneth Widder, Jay Lichter, Nathan L. Mata
Abstract: Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
Type:
Application
Filed:
May 17, 2012
Publication date:
November 15, 2012
Applicant:
Revision Therapeutics, Inc.
Inventors:
Kenneth Widder, Jay Lichter, Nathan L. Mata
Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
Type:
Application
Filed:
September 13, 2011
Publication date:
September 20, 2012
Applicant:
ReVision Therapeutics, Inc.
Inventors:
Nathan L. Mata, Yun Han, Kenneth Widder, Jay Lichter
Abstract: Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.
Abstract: We describe methods and compositions for treating ophthalmic conditions associated with angiogenesis, vascular leakage, and/or damage to ganglia.
Type:
Application
Filed:
May 3, 2010
Publication date:
May 3, 2012
Applicant:
REVISION THERAPEUTICS, INC.
Inventors:
Nathan L. Mata, Sujatha Narayan, Natalis Tsivkovskaia
Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
Type:
Application
Filed:
May 27, 2011
Publication date:
December 1, 2011
Applicant:
ReVision Therapeutics, Inc.
Inventors:
Kenneth Widder, Jay Lichter, Nathan L. Mata
Abstract: Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.
Type:
Grant
Filed:
September 15, 2008
Date of Patent:
July 5, 2011
Assignee:
Revision Therapeutics, Inc.
Inventors:
Nathan L. Mata, Kim B. Phan, Tam V. Bui, Mustapha Haddach
Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
Type:
Application
Filed:
April 21, 2010
Publication date:
November 25, 2010
Applicant:
REVISION THERAPEUTICS, INC.
Inventors:
Kenneth WIDDER, Jay LICHTER, Nathan L. MATA